Anti-pd-l1 antibodies and diagnostic uses thereof
AssigneesVentana Medical Systems, Inc., Spring BioScience Corporation
InventorsMarcin KOWANETZ, Hartmut KOEPPEN, Zachary BOYD, Zhiming LIAO, Yifei ZHU, Bharathi VENNAPUSA, Patrick C. ROCHE
Life of this patent
Estimating the term…
Abstract
The invention provides programmed death-ligand 1 (PD-L1) antibodies and methods of using the same.
Claims20
A method for predicting responsiveness of a subject suffering from a cancer to treatment with an anti-cancer therapy comprising a PD-1 axis binding antagonist, the method comprising:
- determining the presence or expression level of PD-L1 in a tumor sample obtained from the subject by contacting the tumor sample with an anti-PD-L1 antibody and detecting the presence of the bound antibody, wherein the presence or expression level of PD-L1 in the sample indicates that the subject is more likely to respond to treatment with an anti-cancer therapy comprising a PD-1 axis binding antagonist, and wherein the antibody comprises the following hypervariable regions (HVRs):
- (a) an HVR-H1 comprising the amino acid sequence of SNGLT (SEQ ID NO:
- 2);
- (b) an HVR-H2 comprising the amino acid sequence of TINKDASAYYASWAKG (SEQ ID NO:
- 3);
- (c) an HVR-H3 comprising the amino acid sequence of IAFKTGTSI (SEQ ID NO:
- 4);
- (d) an HVR-L1 comprising the amino acid sequence of QASESVYSNNYLS (SEQ ID NO:
- 9);
- (e) an HVR-L2 comprising the amino acid sequence of LASTLAS (SEQ ID NO:
- 10);
- and
- (f) an HVR-L3 comprising the amino acid sequence of IGGKSSSTDGNA (SEQ ID NO:
- 11).
A method for determining the likelihood that a subject suffering from a cancer will exhibit benefit from treatment with an anti-cancer therapy comprising a PD-1 axis binding antagonist, the method comprising:
- determining the presence or expression level of PD-L1 in a tumor sample obtained from the individual by contacting the tumor sample with an anti-PD-L1 antibody and detecting the presence of the bound antibody, wherein the presence or expression level of PD-L1 in the sample indicates that the subject is likely to respond to treatment with an anti-cancer therapy comprising a PD-1 axis binding antagonist, and wherein the antibody comprises the following hypervariable regions (HVRs):
- (a) an HVR-H1 comprising the amino acid sequence of SNGLT (SEQ ID NO:
- 2);
- (b) an HVR-H2 comprising the amino acid sequence of TINKDASAYYASWAKG (SEQ ID NO:
- 3);
- (c) an HVR-H3 comprising the amino acid sequence of IAFKTGTSI (SEQ ID NO:
- 4);
- (d) an HVR-L1 comprising the amino acid sequence of QASESVYSNNYLS (SEQ ID NO:
- 9);
- (e) an HVR-L2 comprising the amino acid sequence of LASTLAS (SEQ ID NO:
- 10);
- and
- (f) an HVR-L3 comprising the amino acid sequence of IGGKSSSTDGNA (SEQ ID NO:
- 11).
A method for selecting an anti-cancer therapy comprising a PD-1 axis binding antagonist for a subject suffering from a cancer, the method comprising:
- determining the presence or expression level of PD-L1 in a tumor sample obtained from the individual by contacting the tumor sample with an anti-PD-L1 antibody and detecting the presence of the bound antibody, wherein the antibody comprises the following hypervariable regions (HVRs):
- (a) an HVR-H1 comprising the amino acid sequence of SNGLT (SEQ ID NO:
- 2);
- (b) an HVR-H2 comprising the amino acid sequence of TINKDASAYYASWAKG (SEQ ID NO:
- 3);
- (c) an HVR-H3 comprising the amino acid sequence of IAFKTGTSI (SEQ ID NO:
- 4);
- (d) an HVR-L1 comprising the amino acid sequence of QASESVYSNNYLS (SEQ ID NO:
- 9);
- (e) an HVR-L2 comprising the amino acid sequence of LASTLAS (SEQ ID NO:
- 10);
- and
- (f) an HVR-L3 comprising the amino acid sequence of IGGKSSSTDGNA (SEQ ID NO:
- 11);
- and
- selecting an anti-cancer therapy comprising a PD-1 axis binding antagonist for the subject based on the presence or expression level of PD-L1 in the sample.
Dependencies are inferred from the claim text.